Tetra Bio-Pharma (TSXV:TBP) announced an acceleration on the application process for two of its cannabis drug products.

As quoted in the press release:


Tetra Bio-Pharma, a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.

This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs. According to Dr. Guy Chamberland, Interim CEO and CSO, “the corporation has performed its own clinical trials and has sufficient quality and clinical trial data to initiate the application for the registration of PPP001 and PPP005 under the Directive 2001/83/EC. Tetra intends to pursue a Full Market Authorization since it has a dossier supporting the medicinal product’s quality, safety, and efficacy.”

All of Tetra’s clinical trials were performed with the same quality of evidence required by the National Competent authorities approving medicines/drugs. Tetra has completed several well-designed safety, pharmacodynamic and pharmacokinetic studies in healthy volunteers and also has two ongoing, well-designed clinical trials in patients. These trials are all double-blind, randomized and placebo controlled.

Click here to read the full press release.

Source: globenewswire.com

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less

Sales to Commence Immediately at The Apothecarium Phillipsburg

 TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that it has received the final permit from the NJ Department of Health (“NJ DOH”) to dispense medical cannabis from its first dispensary in New Jersey . The 3,500 square-foot dispensary, located at 55 South Main Street in downtown Phillipsburg is situated in the historic Phillipsburg National Bank & Trust building and is the first Alternative Treatment Center (“ATC”) in Warren County .

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of a customer rewards program called “Insider Rewards” for its Urban Juve skin care line.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/68816_d5e319fef42e2b1a_001.jpg

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less